William Blair Weighs in on Exagen’s Q1 Earnings (NASDAQ:XGN)

Exagen Inc. (NASDAQ:XGN) – Equities research analysts at William Blair upped their Q1 2025 earnings estimates for Exagen in a report released on Wednesday, March 12th. William Blair analyst A. Brackmann now expects that the company will post earnings per share of ($0.20) for the quarter, up from their previous estimate of ($0.24). William Blair has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.55) EPS.

A number of other research firms have also issued reports on XGN. Canaccord Genuity Group lifted their price objective on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 price objective on shares of Exagen in a research note on Monday, January 13th.

Exagen Trading Up 6.3 %

NASDAQ XGN opened at $3.56 on Friday. The firm has a market capitalization of $62.79 million, a price-to-earnings ratio of -3.79 and a beta of 1.40. The company’s 50 day moving average price is $3.78 and its 200 day moving average price is $3.58. Exagen has a one year low of $1.30 and a one year high of $6.22. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05.

Institutional Trading of Exagen

A number of hedge funds have recently made changes to their positions in XGN. Verus Capital Partners LLC acquired a new stake in shares of Exagen during the third quarter worth approximately $39,000. Stonepine Capital Management LLC grew its position in shares of Exagen by 49.0% during the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after buying an additional 175,701 shares in the last quarter. Palumbo Wealth Management LLC grew its position in shares of Exagen by 13.5% during the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock worth $355,000 after buying an additional 10,340 shares in the last quarter. Corient Private Wealth LLC acquired a new stake in shares of Exagen during the fourth quarter worth approximately $45,000. Finally, Virtu Financial LLC acquired a new stake in shares of Exagen during the fourth quarter worth approximately $46,000. Institutional investors and hedge funds own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).